Jinwu Financial News | BOCOM INTL predicts that commercial insurance will further develop by 2025, helping to solve the payment issues for Innovative Drugs. At the same time, the differentiated innovative payment mechanism combining Class B catalog and commercial insurance may alleviate the challenges faced by Innovative Drug and Device companies regarding hospital access and reimbursement payments. Recently, after significant fluctuations, the Pharmaceutical Sector has seen a slight decline. Considering that sector valuations are still at historical lows, coupled with the subsequent favorable policies from finance and health insurance/commercial insurance + improved liquidity, the bank believes there is still room for further recovery.
The bank continues to recommend potential beneficiary symbols with subsequent policy space, including: 1) AKESO (09926), Legend Biotech, and Genscript Biotech (01952), which are Innovative Drug symbols with rich short-term catalysts, high growth profitability or clear breakeven points, and substantial room for valuation recovery; 2) SIMCERE PHARMA (02096) and SINO BIOPHARM (01177), which are leading prescription drug companies with potential for joint recovery in performance growth and valuation multiples. The bank also suggests focusing on: 1) Private Medical Services and aesthetic medical symbols with strong Consumer attributes; 2) Pharmaceutical Commerce circulation symbols with high dividend yields that are expected to benefit from overall industry fundamental improvements.